Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by APG Asset Management US Inc.

APG Asset Management US Inc. raised its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,696 shares of the medical research company’s stock after acquiring an additional 351 shares during the period. APG Asset Management US Inc.’s holdings in Charles River Laboratories International were worth $2,987,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tortoise Investment Management LLC boosted its holdings in Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after buying an additional 57 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Charles River Laboratories International in the first quarter valued at approximately $41,000. Brown Brothers Harriman & Co. grew its stake in Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after purchasing an additional 95 shares in the last quarter. Sunbelt Securities Inc. raised its holdings in Charles River Laboratories International by 1,072.7% in the first quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 236 shares in the last quarter. Finally, Concord Wealth Partners lifted its position in shares of Charles River Laboratories International by 362.5% during the 1st quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock worth $70,000 after purchasing an additional 203 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Up 2.8 %

Shares of NYSE CRL opened at $198.26 on Friday. Charles River Laboratories International, Inc. has a 12-month low of $161.65 and a 12-month high of $275.00. The stock has a fifty day moving average price of $207.54 and a 200 day moving average price of $222.21. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The company has a market cap of $10.24 billion, a P/E ratio of 23.32, a P/E/G ratio of 4.09 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.41. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. Research analysts anticipate that Charles River Laboratories International, Inc. will post 10.01 EPS for the current fiscal year.

Charles River Laboratories International announced that its board has authorized a share repurchase program on Wednesday, August 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 9.6% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Evercore ISI reduced their price target on shares of Charles River Laboratories International from $265.00 to $225.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Baird R W cut shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 8th. Argus restated a “hold” rating on shares of Charles River Laboratories International in a research report on Friday, June 28th. UBS Group cut their target price on shares of Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Finally, TD Cowen decreased their price objective on Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating on the stock in a report on Monday, August 12th. Ten research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of “Hold” and a consensus target price of $227.55.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).